Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

By C. Antonescu, P. Besmer, T. Guo, K. Arkun, Glory Hom, Beata Koryotowski, M. Leversha, P. Jeffrey, D. Desantis, S. Singer and 3 more. Clinical Cancer Research, 2005

815 citations recorded by the source corpus.

Subfields: Gastroenterology, Hematology

View Paper: https://www.semanticscholar.org/paper/1e0796b7aadb666a5e72afb224bbbcdb784f55ba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Christopher Corless
2. M. Heinrich

In Hematology

1. M. Heinrich
2. Christopher Corless

Citations in the corpus

• Liquid Biopsies: Genotyping Circulating Tumor DNA (2014, background): “The genetic bases of secondary resistance to various targeted drugs have been elucidated in great detail.(71,72) The most extensive analyses are those involving patients with Philadelphia chromosome–positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor imatinib.”
• Gastrointestinal stromal tumours: origin and molecular oncology (2011, background): “In general, GISTs are heterozygous for a given mutation; however, in approximately 15% of tumours, the remaining wild-type KIT allele is lost, and this allele loss is associated with malignant behaviou”